Orthofix Medical/$OFIX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Orthofix Medical

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Ticker

$OFIX
Sector
Primary listing

Employees

1,616

Orthofix Medical Metrics

BasicAdvanced
$589M
-
-$3.18
0.82
-

What the Analysts think about Orthofix Medical

Analyst ratings (Buy, Hold, Sell) for Orthofix Medical stock.

Bulls say / Bears say

Orthofix delivered first quarter 2025 pro forma net sales of $189.2 million, up 4.3% year-over-year, driven by 11% constant-currency growth in Global Orthopedics and a 200 basis-point expansion in adjusted EBITDA margin (Business Wire).
The TrueLok Elevate Transverse Bone Transport System received FDA 510(k) clearance and CE Mark in March 2025, marking Orthofix’s first dedicated TBT device and opening access to an estimated $1.2 billion diabetic wound market (Business Wire).
Wall Street consensus remains constructive, with analysts on average rating OFIX a “buy” and a median 12-month price target of $24, implying roughly 77% upside from recent levels (Reuters.)
Although reported net sales increased, Orthofix widened its net loss to $53.1 million, or $1.35 per share, in Q1 2025, underscoring persistent profitability challenges amid ongoing investments in growth initiatives (Business Wire).
In May 2025, Orthofix reduced its full-year 2025 net sales guidance to $808 million–$816 million from the prior range of $818 million–$826 million, reflecting short-term headwinds from targeted commercial transitions and NGO impacts (Business Wire).
In March 2025, Kuehn Law initiated an investigation into Orthofix, alleging that certain officers and directors may have breached their fiduciary duties by misrepresenting management conduct, exposing the company to potential litigation and reputational risk (GlobeNewswire.)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Orthofix Medical Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Orthofix Medical Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OFIX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs